Summit Corporation Aktie
WKN DE: A115K3 / ISIN: GB00BN40HZ01
23.04.2025 22:05:00
|
Why Summit Therapeutics Rocketed Double-Digits Today
Shares of lung cancer biotech Summit Therapeutics (NASDAQ: SMMT) rocketed 14.7% on Wednesday as of 1:45 p.m. ET.The markets were broadly up today on a potential easing of trade tensions with China. That should be a positive for Summit, as its main partner for its current lung cancer drug trials is Chinese biotech Akeso (OTC: AKES.F).But the real reason for the market-beating performance today was more good news regarding a phase III trial for Summit's breakthrough drug, ivonescimab.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!